Dermata Therapeutics is a biotechnology business based in the US. Dermata Therapeutics shares (DRMA) are listed on the NASDAQ and all prices are listed in US Dollars. Dermata Therapeutics employs 8 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $0.27 |
|---|---|
| 52-week range | $0.16 - $2.45 |
| 50-day moving average | $0.37 |
| 200-day moving average | $0.63 |
| Wall St. target price | $6.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.85 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.2739 from 2023-01-31
| 1 week (2023-01-26) | -4.23% |
|---|---|
| 1 month (2022-12-30) | -33.03% |
| 3 months (2022-11-02) | -57.86% |
| 6 months (2022-08-02) | -48.99% |
| 1 year (2022-02-02) | -87.66% |
|---|---|
| 2 years (2021-02-02) | -99.45% |
| 3 years (2020-01-31) | 50 |
| 5 years (2018-02-02) | 50 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -58.01% |
| Return on equity TTM | -105.15% |
| Profit margin | 0% |
| Book value | $0.62 |
| Market capitalisation | $3.5 million |
TTM: trailing 12 months
We're not expecting Dermata Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
Dermata Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California. .
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.